Akthelia Pharmaceuticals was established to advance the inventions of the founders that show that small molecules can stimulate the innate immunity to cure infections. The company develops anti-infective therapies that contain these small molecules. The drug development is based on research conducted at the University of Iceland and the Karolinska Institute in Stockholm. Akthelia’s therapies employ a mechanism of action that is unlike any anti-infective therapy currently used in the treatment of infectious disease. These treatments could be used to eliminate bacterial strains that are resistant to classical treatments. Akthelia has filed two patent applications and is conducting pre-clinical and clinical studies to investigate the efficacy of its small molecule therapies in gastro-intestinal and respiratory infections. Akthelia is seeking collaborators to further advance the drug development.

Akthelia's website:www.akthelia.com


Page style: